Table 4.
Parameter | Case | Day 0 (presentation) | Week 1 (days 1–7) | Week 2 (days 8–14) | Weeks 4–5 (days 22–35) | Week 10 (days 64–70) | Week 17 (days 113–119) | Weeks 38–39 (days 260–273) | Week 122 (days 848–854) |
---|---|---|---|---|---|---|---|---|---|
Intraerythrocytic inclusions | 1 | positive | positive | positive | na | positive | positive | negative | na |
2 | positive | positive | positive | na | positive | negative | negative | na | |
3 | positive | positive | positive | na | positive | negative | negative | na | |
4 | negative | positive | positive | negative | na | na | negative | na | |
5 | na | na | na | na | na | na | na | na | |
PCR for Cytauxzoon sp.a | 1 | na | positive | na | positive | positive | positive | positive | positive |
2 | positive | positive | na | positive | positive | positive | positive | positive | |
3 | positive | positive | na | positive | positive | positive | positive | positive | |
4 | negative | positive | na | positive | na | na | negative | na | |
5 | na | na | na | positive | na | na | na | na |
Note: Cases 1–3 were treated with azithromycin and atovaquone from day 1 to 10 and from day 77 to 86. Case 4 was treated with azithromycin from day 6 to 21 and from day 260 to 270 and with atovaquone from day 11 to 21
Abbreviation: na not applicable
aScreened by real-time PCR and confirmed by conventional PCR and sequencing